BACKGROUND AND PURPOSE: Erectile function (EF) is commonly affected following prostate cancer treatment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
We aim to evaluate the long-term EF following seed brachytherapy (BT) treatment.
MATERIALS AND METHODS: The study consisted of 366 patients treated with BT at our institution, who completed the IIEF-5 questionnaire and reported no or mild erectile dysfunction (ED) pre-BT. The probability of EF preservation post-BT was estimated using the Kaplan-Meier methods. The difference in EF preservation by patient-, tumour- and treatment-related factors was assessed using the log-rank test. Multivariate Cox regression was used to estimate the effect of each factor on EF preservation.
RESULTS: Of the 366 patients, 277 (76%) reported normal EF, and 89 (24%) reported mild ED. The patients were followed-up for a median of 41months (range: 3-124), and the 5-year actuarial rate of EF preservation was 59%. Age at BT seed implant, presence of medical comorbidities, Gleason score and the biologically effective dose (BED) are associated with EF preservation (P< 0.005). The association for these four factors remains statistically significant in multivariate analysis, with Gleason score having the strongest effect (HR=3.7; 95% CI=2.6-5.4).
CONCLUSION: The 5-year actuarial rate of EF preservation post-BT in our cohort is 59%, and is influenced by multiple factors.
Ong WL, Hindson BR, Beaufort C, Pharoah P, Millar JL. Are you the author?
William Buckland Radiotherapy Centre, Alfred Health, Melbourne, Australia; Department of Public Health and Primary Care, University of Cambridge, United Kingdom; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Reference: Radiother Oncol. 2014 Jul 30. pii: S0167-8140(14)00258-8.